MarketScreener Homepage > Equities > Swiss Exchange > Roche Holding AG ROG CH0012032048

Report

Delayed Swiss Exchange - 10/26 08:55:49 am
298.35	CHF		+0.32%

10/23

CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results

10/22

ROCHE HOLDINGS AG : Goldman Sachs maintains a Buy rating

10/22

PTC THERAPEUTICS : Evrysdi Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

10/20/2020	10/21/2020	10/22/2020	10/23/2020	10/26/2020	Date
307.05(c)	299.15(c)	297.25(c)	297.4(c)	298.35	Last
1 697 398	2 767 307	2 450 057	2 046 400	452 295	Volume
-1.41%	-2.57%	-0.64%	+0.05%	+0.32%	Change

More quotes

Financials

Sales 2020	60 385 M 66 677 M 66 677 M
Net income 2020	14 670 M 16 199 M 16 199 M
Net cash position 2020	3 206 M 3 540 M 3 540 M
P/E ratio 2020	17,7x
Yield 2020	3,13%

Sales 2021	63 259 M 69 850 M 69 850 M
Net income 2021	16 031 M 17 701 M 17 701 M
Net cash position 2021	12 035 M 13 289 M 13 289 M
P/E ratio 2021	15,9x
Yield 2021	3,24%

Capitalization	254 B 281 B 281 B
EV / Sales 2020	4,16x
EV / Sales 2021	3,83x
Nbr of Employees	97 735
Free-Float	83,6%

More Financials

Company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The...

Sector

Pharmaceuticals

Calendar

11/09

Presentation

More about the company

Notations Surperformance© of Roche Holding AG

Trading Rating :

Investor Rating :

More Ratings

All news about ROCHE HOLDING AG

10/23	CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results	AQ
10/22	ROCHE HOLDINGS AG : Goldman Sachs maintains a Buy rating	MD
10/22	PTC THERAPEUTICS : Evrysdi Continues to Make Global Progress for the Treatment o..	AQ
10/22	ROCHE : Atea team up on potential COVID-19 pill	RE
10/22	ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..	PU
10/22	ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..	PU
10/22	ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..	AQ
10/22	ROCHE : Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Dev..	AQ
10/22	Roche announces collaboration with Atea Pharmaceuticals to develop a potentia..	GL
10/21	ROCHE : COVID SCIENCE-COVID-19 complication rates far higher than for flu; open ..	RE
10/21	PROTHENA : Shares Rise 7% on Prasinezumab Study With Roche	DJ
10/21	PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed	DJ
10/21	ROCHE : and Prothena will Advance Prasinezumab into Late-Stage Clinical Developm..	AQ
10/20	ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..	AQ
10/20	Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..	AQ

More news

News in other languages on ROCHE HOLDING AG

10/23	Roche compte continuer à se développer sur le continent africain
10/23	AVIS D'ANALYSTES DU JOUR : Air France-KLM, BioMérieux, Logitech, Michelin, Nestl..
10/22	ROCHE HOLDINGS AG : Goldman Sachs toujours positif
10/22	Goldman senkt Ziel für Roche - 'Conviction Buy List'
10/22	ROCHE : nouveau partenariat dans la lutte contre le Covid-19

More news

Analyst Recommendations on ROCHE HOLDING AG

10/22	ROCHE HOLDINGS AG : Goldman Sachs maintains a Buy rating	MD
10/19	ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating	MD
10/16	ROCHE HOLDINGS AG : UBS keeps its Buy rating	MD

More recommendations

Stock Trading Strategies

	ROCHE HOLDING AG - 08/19
Close to an important medium term support level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Roche : sees problems from warehouse glitch in Britain 'cleared out' by weekend